BIOMARKERS IN RHEUMATOLOGY, WHAT DO WE REALLY KNOW?

Sa？etak The diagnosis of rheumatic diseases is made mostly on the basis of clinical signs and symptoms. However, we rheumatologists very oft en rely on serological and proteomic biomarkers that help to our pure clinical judgement, which is a central element of medical profession. Identifying biomarkers that can contribute the diagnosis, efficacy measurement, prognosis and treatment selection will be described in this paper. Personalized treatment strategy in the daily clinic using genomic, transcriptomic and proteomic screening is the era of the future medicine. However, heterogeneous manifestations of rheumatic diseases make interpreting of some conflicting results on biomarkers difficult. Therefore, multibiomarker approach may prove useful. In this paper, several well-established and novel biomarkers that have already been incorporated to the routine clinical setting or that are just studied for diagnostic and prognostic purposes will be discussed. References: 1. Jog NR, James JA. Biomarkers in connective tissue diseases. J Allergy Clin Immunol. 2017 Dec;140(6):1473–1483 2. Miossec P, Verweij CL, Klareskog L, et al; Group for Respect of Ethics and Excellence in Science (GREES). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis. 2011 Oct;70(10):1713–8. 3. Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis. 2013 Jan;72(1):3–6